MMI’s surgical robot saves a person’s arm from amputation


[Image from Medical Microinstruments]

Medical Microinstruments (MMI) said today that its Symani Surgical System had a successful post-traumatic limb reconstruction procedure that saved a patient’s arm from amputation.

MMI, based in Italy, designed the Symani system as a flexible platform with two robotic arms that can be easily positioned for surgical procedures in any anatomical region.

Symani has a 7-20X motion scale with tremor filtration for microsurgery and super microsurgery. Surgeons can adapt hand movements while articulating the NanoWrist robotic micro-instruments. NanoWrist has seven degrees of freedom for optimal dexterity within minimally invasive incisions.

The reconstruction procedure was performed at the Careggi University Hospital in Florence by Dr Marco Innocenti and was the first patient enrolled in the post-marketing study of the Italy-based company. The young adult in the procedure was a candidate for free flap reconstruction to save the arm after amputation was recommended. The robot-assisted procedure was successful in restoring blood flow to the area despite severe damage and extensive scar tissue on the inside of the arm, according to the company.

“Robot-assisted technology is a revolutionary tool for microsurgery, as it allows physicians to perform difficult or impossible procedures with the human hand,” said Innocenti. “By increasing our precision, we can reconnect submillimeter vessels and nerves that allow reconstruction even after severe trauma. I am confident that our post-market study will show significant benefits in improving patient outcomes, as the motorcycle accident patient would have lost her arm without robot-assisted microsurgery.

The Symani Surgical System obtained CE mark approval in 2019. It is intended to improve free flap reconstructions, replanting, birth defects, peripheral nerve repairs and lymphatic surgeries. It reduced the occurrence of thrombosis by 50% in preclinical studies, according to the MMI.

“By moving the surgery from one manual process to one that harnesses robotic technology, we can open the door to procedures that have never been done before,” said CEO Mark Toland. Prof. Innocenti’s accomplishment, in this case, is an extremely exciting validation element for our technology that will aid in our data collection for our growing global regulatory strategy.


Comments are closed.